Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?

Reference

• Antonarakis ES, Lu C, Wang C, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. NEJM 2014; 371(11):1028-1038; PMID:25184630; http://dx.doi.org/10.1056/NEJMoa1315815
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncology 2015; 1(5):582-591; PMID:26181238; http://dx.doi.org/10.1001/jamaoncol.2015.1341
   PubMed Web of Science ®Google Scholar
• Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Research 2010; 70(20):7992-8002; PMID:20807808; http:/dx.doi.org/10.1158/0008-5472.CAN-10-0585
   PubMed Web of Science ®Google Scholar
• Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR and Giannakakou P. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 2014; 74: 2270-2282; PMID:24556717; http://dx.doi.org/10.1158/0008-5472.CAN-13-2876
   PubMed Web of Science ®Google Scholar
• Zhang G, Liu X, Li J, Ledet E, Alvarez X, Qi Y, Fu X, Sartor O, Dong Y, Zhang H. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. Oncotarget 2015; 6(27):23358-71; PMID:26160840 [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer 2010; 10:511; PMID:20875115; http://dx.doi.org/doi:10.1186/1471-2407-10-511
   PubMed Web of Science ®Google Scholar
• Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Molecular Cancer Therapeutics 2008; 7(1):19-26; PMID:18187806; http://dx.doi.org/10.1158/1535-7163.MCT-07-0557
   PubMed Web of Science ®Google Scholar
• Pressler H, Sissung TM, Venzon D, Price DK, Figg WD. Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression. PLoS One 2011; 6(5):e.20372; PMID:21625523; http://dx.doi.org/10.1371/journal.pone.0020372
   PubMedGoogle Scholar
• Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Annals of Oncology 2015; 26:1859-1865; PMID:26117829; http://dx.doi.org/10.1093/annonc/mdv282
   PubMed Web of Science ®Google Scholar
• Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 2014; 5(6):1646-56; PMID:24722067
   PubMed Web of Science ®Google Scholar
• Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clinical Cancer Research 2015; 20(6):1590-1600; PMID:24449822; http://dx.doi.org/10.1158/1078-0432.CCR-13-1863
   PubMed Web of Science ®Google Scholar
• Kong D, Sethi S, Li Y, Chen W, Sakr WA, Heath E, Sarkar FH. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. Prostate 2015; 75(2):161-174; PMID:25307492; http://dx.doi.org/10.1002/pros.22901
   PubMed Web of Science ®Google Scholar
• Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP and Gao AC. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration resistant prostate cancer. Clin Cancer Res 2014; 20:3198-3210; PMID:24740322; http://dx.doi.org/10.1158/1078-0432.CCR-13-3296
   PubMed Web of Science ®Google Scholar
• Liu C, Lou W, Armstrong C, Zhu Y, Evans CP and Gao AC. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate 2015; 75(13):1341-53; PMID:25970160; http://dx.doi.org/10.1002/pros.23015
   PubMed Web of Science ®Google Scholar
• Zengerling F, Azoitei A, Herweg A, Jentzmik F, Cronauer MV. Inhibition of IGF1R diminishes transcriptional activity of the androgen receptor and its constitutively active, Cterminally truncated counterparts Q640X and ARV7. World J Urol 2015; PMID:26318637; http://dx.doi.org/10.1007/s00345-015-1674-5 [ Epub ahead of print]
   PubMedGoogle Scholar
• Nadiminity N, Tummala R, Liu C, Lou W, Evans CP, Gao AC. NF-kB2/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Molecular Cancer Therapeutics 2015; 14(8):1884-1895; PMID:26056150; http://dx.doi.org/10.1158/1535-7163.MCT-14-1057
   PubMed Web of Science ®Google Scholar
• Stockley J, Markert E, Zhou Y, Robson CN, Elliott DJ, Lindberg J, Leung HY, Rajan P. The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. Nature Scientific Reports 2015; 5:13426; PMID:26310125; http://dx.doi.org/10.1038/srep13426
   PubMed Web of Science ®Google Scholar
• Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W, Gambhir SS, Lee P, Sartor O, Flemington EK, Zhang H, Hu C, Dong Y. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Research 2015; 75(17):3663-71; PMID:26060018; http://dx.doi.org/10.1158/0008-5472.CAN-15-0381
   PubMed Web of Science ®Google Scholar
• Kwegyir-Afful AK, Ramalingam S, Purushottamachar P, Ramamurthy VP, Njar V. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistance prostate cancer xenografts in vivo. Oncotarget 2015; 6(29):27440-60; PMID:26196320 [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar